Nasdaq

Theratechnologies : EGRIFTA WR Now Available For HIV Patients With Excess Abdominal Fat

(RTTNews) - Theratechnologies Inc. (THTX, TH.TO) announced the availability of EGRIFTA WR (tesamorelin) for injection, approved earlier this year by the U.S. Food and Drug Administration, for the ...
Yahoo Finance

Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy

MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage ...
Monthly Prescribing Reference

Egrifta WR Now Available for HIV-Related Lipodystrophy

A patient support program has been established to transition patients to Egrifta WR, which will gradually replace Egrifta SV. Egrifta WR™, a new concentrated formulation (F8) of tesamorelin, is now ...
Monthly Prescribing Reference

Egrifta Wr

Tesamorelin 11.6mg; per vial; lyophilized pwd for SC inj after reconstitution; preservative-free; contains mannitol. Store at room temperature at 20°C to 25°C (68°F to 77°F) in the original box to ...
Finanznachrichten

Theratechnologies Announces Availability of EGRIFTA WR (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy

Important Safety Information EGRIFTA WR (tesamorelin) for injection is approved in the U.S. for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. EGRIFTA WR is a ...